Therefore, the aforementioned preliminary results highlight the strong need for planning further large, prospective, randomized controlled trials aimed to assess the long-term safety and efficacy of semaglutide and tirzepatide as non-insulin adjunct therapies in both pediatric and adult patients with T1D (at different stages of the disease) and double diabetes, and as anti-hyperglycemic agents in patients with LADA. Here, INS is linked to diabetes mellitus.